Revolution looks to spin into the clinic with $56M series B

Revolution Medicines Inc. (Revmed) strengthened its balance sheet with a $56 million series B while bolstering its C-suite with a trio of executives. The financing will enable the company to advance its lead SHP2 program through IND and into what Mark Goldsmith, president and CEO, called an "exciting" clinical trial program.

 

BioWorld (subscription required)

Return to Media Home